Tasosartan
Jump to navigation
Jump to search
Clinical data | |
---|---|
Pregnancy category |
|
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H21N7O |
Molar mass | 411.469 g·mol−1 |
(what is this?) (verify) |
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References
- ^ Atkinson AJ, et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 978-0-12-369417-1.
- ^ Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm. 57 (13): 1231–41. doi:10.1093/ajhp/57.13.1231. PMID 10902066.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Articles with changed ChemSpider identifier
- Articles without EBI source
- Articles without KEGG source
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Tetrazoles
- Pyridopyrimidines
- Lactams
- Angiotensin II receptor antagonists
- Biphenyls
- All stub articles
- Cardiovascular system drug stubs